In a patient on aspirin who presents with an acute bright‑red rectal bleed, should aspirin be continued at discharge?

Management of Aspirin in Patients with Bright Red Blood Per Rectum

Aspirin should be continued at discharge in patients on aspirin for secondary prevention who present with acute bright red rectal bleeding, and should be restarted as soon as hemostasis is achieved. 1, 2

Critical Distinction: Primary vs Secondary Prevention

The management decision hinges entirely on the indication for aspirin therapy:

Secondary Prevention (Continue Aspirin)

• Aspirin should NOT be routinely stopped in patients taking it for secondary prevention (prior MI, coronary stents, stroke, established cardiovascular disease). 1, 2

• Restart aspirin immediately once hemostasis is achieved, defined as stable hemoglobin over 12-24 hours, no ongoing transfusion requirements, and no evidence of active bleeding. 2, 3

• The mortality benefit is dramatic: a prospective RCT demonstrated 1.3% mortality in patients who continued aspirin versus 12.9% in those who stopped, despite a small increase in rebleeding (10.3% vs 5.4%, with no fatal rebleeds). 2

• Patients who discontinue aspirin face a nearly 7-fold increased risk of death or acute cardiovascular events (HR 6.9,95% CI 1.4-34.8) compared to those who continue therapy. 4

• A separate study showed discontinuing aspirin resulted in HR 5.77 for thrombotic events and HR 3.32 for mortality compared to restarting therapy. 2

Primary Prevention (Discontinue Aspirin)

• Aspirin for primary prophylaxis should be permanently discontinued after lower GI bleeding. 1, 2, 3

• The bleeding risk outweighs any cardiovascular benefit in the primary prevention population. 3

Timing of Aspirin Resumption

For secondary prevention patients, restart aspirin within 24-48 hours once bleeding has stopped, not at some distant future date. 3

• Most rebleeding occurs within the first 5 days after the index bleeding event in patients on antiplatelet agents. 1

• For patients with recent coronary stents (<12 months), aspirin should be restarted within 24 hours if at all possible, as the thrombotic risk is extremely high. 3

• The maximum delay should not exceed 5-7 days even if bleeding control is challenging. 3

Special Considerations for High-Risk Cardiac Patients

If the patient is on dual antiplatelet therapy (DAPT) with coronary stents:

• Continue aspirin if possible and only temporarily interrupt the P2Y12 receptor antagonist (clopidogrel, ticagrelor, prasugrel). 2

• Restart the P2Y12 inhibitor within 5 days maximum due to extremely high risk of stent thrombosis after this timeframe. 1, 2

• Discontinuing aspirin in patients with coronary stents carries a threefold increased risk of major adverse cardiac events, increasing to an OR of 89 for patients with stents. 2

• Coordinate management with an interventional cardiologist for patients with recent stent placement. 2, 3

Management Algorithm

1. Assess aspirin indication immediately:

   • Secondary prevention (prior MI, stents, stroke, PAD) → Plan to continue 1, 2
   • Primary prevention → Permanently discontinue 1, 2, 3

2. During acute bleeding phase:

   • Resuscitate and achieve hemostasis through endoscopic, radiological, or surgical means 1, 2
   • Aspirin may be temporarily held during life-threatening hemorrhage 3
   • For secondary prevention, aspirin can often be continued even during evaluation if bleeding is not severe 3

3. At discharge (secondary prevention patients):

   • Restart aspirin as soon as hemostasis is documented 1, 2
   • Ensure patient is on high-dose PPI therapy to reduce rebleeding risk 5
   • Document clear plan for antiplatelet continuation in discharge summary 2

Common Pitfalls to Avoid

• Never permanently discontinue aspirin in secondary prevention patients without cardiology consultation, as this dramatically increases mortality risk. 2, 4

• Do not delay aspirin resumption for weeks or months in secondary prevention patients once bleeding has stopped—the thrombotic risk escalates rapidly. 3, 4

• Avoid stopping both antiplatelet agents simultaneously in patients on DAPT, as median time to stent thrombosis is only 7 days if both are discontinued. 6

• Do not give platelet transfusions routinely to patients on aspirin with GI bleeding, as this does not reduce rebleeding but is associated with higher mortality. 6

• Recognize that the small increase in rebleeding risk (approximately 5% excess) is vastly outweighed by the mortality benefit in secondary prevention patients. 2